Dercum’s disease is a rare disorder that affects painful growths of fatty tissue called lipomas. Fat tissue is known as loose connective tissue, hence Dercum’s disease is a loose connective tissue disease. The lipomas mainly occur on the trunk, the upper arms, and upper legs and are found just below the skin but also can be found deeper in the body coupled to muscle, tendons, ligaments, or bone by connective tissue. Pain associated with Dercum’s disease can often be severe. Furthermore, the rising prevalence of rare diseases, the increasing research and development activities. However, a lack of awareness among the people about the disease may hamper the growth of the global Dercum’s disease market. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their drugs and devices and signing contracts and agreements to broaden their reach and reduce operational costs.
The global Dercum’s disease market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.
The business model developed by manufacturers in the global Dercum’s disease market includes manufacturing advanced Dercum’s disease medication products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key Dercum’s disease market manufacturers are also focusing on investing in R&D activities. This will boost the market growth in the upcoming future.
With respect to the current scope of the report, Johnson & Johnson (US) is the top player in the global Dercum’s disease market due to its strong product offering and high preference for its products by customers. Pfizer Inc (US) is the second major player, followed by Abbvie, Inc (US), Novartis International AG (Switzerland), and GlaxoSmithKline plc (UK). Other key players contributing to the market growth include Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), and BHR Pharmaceuticals Ltd (UK).
Threat of New Entrants
The threat of new entrants in the global Dercum’s disease market is low. Any manufacturing company trying to enter the market is required to accept and abide by the mandatory regulatory standards set by the respective regulatory authorities of the country, such as the Food and Drug Administration (FDA), The Central Drugs Standard Control Organization (CDSCO), and others. Moreover, the market is also characterized by a reasonable degree of brand loyalty, where establishing a brand name is difficult for newcomers. Furthermore, the cost involved in the R&D of a product is comparatively high, which does not allow new players to enter the market easily.
Bargaining Power of Suppliers
The bargaining power of suppliers in the global Dercum’s disease market is moderate. The suppliers in the Dercum’s disease market are the developers and manufacturers of devices used for treating Dercum’s. The bargaining power of suppliers is a crucial factor in the global Dercum’s disease market and determines the strength of the industry. Many suppliers are currently present in the market due to the availability of a huge patient pool, high demand for Dercum’s treatment, and increasing government support. The existing key companies capture significant market share and monitor the costs of the devices. The switching cost of these suppliers is moderate because suppliers tend to enter long-term associations, partnerships, and deals with other manufacturing companies. The overall bargaining power of suppliers in the global Dercum’s disease market is hence moderate.
Threat of Substitutes
The threat of substitutes in the global Dercum’s disease market is low. Patients suffering from Dercum’s disease have surgical, medication, liposuction, electrotherapy, acupuncture treatment options that show promising results. Furthermore, many large- and medium-scale companies manufacture different types of devices and medications for Dercum’s treatment. Some small companies are providing their products at low prices to sustain themselves in this highly competitive market.
Bargaining Power of Buyers
The bargaining power of buyers is high in the global Dercum’s disease market. This is primarily due to the presence of a growing number of buyers in the industry. The market for Dercum’s disease is identified as having a significant customer base, considering the increasing number of rare diseases, and rising research and development activities. However, the buyers tend to use the products that have been provided by the top players irrespective of the pricing. Therefore, the bargaining power of buyers is high in the global Dercum’s disease market.
Intensity of Rivalry
The overall degree of competition in the global Dercum’s disease market is high. The number of competitors is high and offers a wide variety of products for Dercum’s disease. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. The companies engaged in manufacturing drugs and treatments are developing advanced products for differentiating their brand from the competitors. Also, many prominent market players are entering into strategic partnerships, co-development activities, and tie-ups with established companies to overcome the competition.
